Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2014

View Archived Issues

Nihon Medi-Physics and Endocyte sign license agreement for companion diagnostic

Moderna launches new venture to focus on development of mRNA Therapeutics in oncology

Elixir Medical confirms first commercial implant of the DESolve scaffold system

Sanofi and Fraunhofer-Gesellschaft form natural product center of excellence for infectious diseases

Mass General, Broad Institute and Amgen form collaboration to treat IBD

IntegraGen enters collaboration to validate oncology biomarker

Resverlogix reports results from analysis of combined data from SUSTAIN and ASSURE trials

Patch under development by Taisho and Tokuhon shows efficacy in phase III trials in osteoarthritis

Tafinlar receives FDA breakthrough therapy designation for NSCLC with BRAF mutation

TS-734 shows promise as PET-imaging agent for early detection and treatment of Alzheimer's disease

Nab-paclitaxel shows promise in esophageal squamous cell carcinoma trial

Identification of a risk factor inversely correlated with cardiometabolic disease

Cytonet files MAA with EMA for use of liver cell therapy to treat urea cycle disorders in children

Japan Tobacco and Torii gain approval for Riona Tablets in Japan

Suglat tablets approved for treatment of type 2 diabetes in Japan

Xyzal syrup for allergic disease gains approval in Japan

SYK inhibitors revealed in Portola patents

Status updates provided for phase III METIV-HCC and ATTENTION trials of tivantinib

Metabotropic glutamate mGlu5 receptor PAMs reported in Vanderbilt University patent

Takeda obtains approval of Adcetris for treatment of malignant lymphoma in Japan

Merck & Co. researchers report discovery of SYK inhibitors

Torii's sublingual immunotherapy drug for Japanese cedar pollinosis approved in Japan

Japanese MHLW approves Bayer's Adempas for CTEPH

FDA committee votes against approval of rivaroxaban for ACS indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...